[To the prevention of recurrent dacryocystitis after surgical treatment].
The efficacy of collagenase KK was evaluated in the treatment of 121 patients with lacrimal duct diseases. Collagenase KK used to prevent recurrent lacrimal duct disease contributed to a significant relief of an inflammatory process (by an average of 2.04+/-0.2 days as rapidly as in the controls), recovery of nasal lacrimation, shorter treatment (by an average of 1.8+/-0.11 bed/days), a reduction in the number of complications (by 2.1 times). The findings enable the authors to recommend the agent for wide clinical application in combination with other treatments.